Published in Parasitol Res on April 04, 2012
Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum. J Immunol (2015) 0.80
Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models. PLoS Negl Trop Dis (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med (1989) 11.36
The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg (2001) 6.02
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A (1991) 4.95
Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol (1992) 4.92
IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol (1992) 4.43
Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol (2011) 3.62
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Expression cloning of a protective Leishmania antigen. Science (1995) 2.83
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med (2005) 2.50
Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog (2005) 2.19
Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev (2004) 2.12
Immunity in kala-azar. Trans R Soc Trop Med Hyg (1961) 2.00
Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis (1992) 1.99
The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J Exp Med (2001) 1.80
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol (2001) 1.67
Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol (1998) 1.65
IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol (2009) 1.63
Serodiagnosis of leishmaniasis. Crit Rev Microbiol (1995) 1.63
Evolution of nuclear ribosomal RNAs in kinetoplastid protozoa: perspectives on the age and origins of parasitism. Proc Natl Acad Sci U S A (1993) 1.62
IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 1.53
Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec (2002) 1.52
Stage-specific, strain-specific, and cross-reactive antigens of Leishmania species identified by monoclonal antibodies. Infect Immun (1982) 1.48
Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun (1995) 1.44
Evolution of the genus Leishmania revealed by comparison of DNA and RNA polymerase gene sequences. Mol Biochem Parasitol (1997) 1.43
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun (2003) 1.38
Immune response to Leishmania infection. Indian J Med Res (2004) 1.36
Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev (2008) 1.35
The role of host genetics in leishmaniasis. Trends Parasitol (2009) 1.34
The molecular evolution of Trypanosomatidae. Adv Parasitol (2001) 1.33
The leishmaniases--survival and expansion in a changing world. A mini-review. Mem Inst Oswaldo Cruz (2007) 1.22
Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol (1993) 1.22
Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice. Exp Parasitol (1996) 1.19
Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo (2009) 1.19
Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc Trop Med Hyg (2002) 1.17
Evaluation and reporting of enzyme immunoassay determinations of antibody to herpes simplex virus in sera and cerebrospinal fluid. J Clin Microbiol (1982) 1.13
Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur J Immunol (2010) 1.11
Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res (2003) 1.07
Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res (2008) 1.07
Description of a dermatropic Leishmania close to L. killicki (Rioux, Lanotte & Pratlong 1986) in Algeria. Trans R Soc Trop Med Hyg (2009) 1.04
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01
The role of macrophage receptors in adhesion and uptake of Leishmania mexicana amastigotes. J Cell Sci (1995) 0.95
Immunologic memory in cutaneous leishmaniasis. Cell Microbiol (2005) 0.94
Vaccination against cutaneous leishmaniasis: current status. Am J Clin Dermatol (2002) 0.90
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89
Cytokines and their STATs in cutaneous and visceral leishmaniasis. J Biomed Biotechnol (2010) 0.87
Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg (2012) 0.86
What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Med Microbiol Immunol (2009) 0.85
Heterologous protection in murine cutaneous leishmaniasis. Immunol Cell Biol (1987) 0.83
Zoonotic cutaneous leishmaniasis in Saudi Arabia: lesions healing naturally in man followed by a second infection with the same zymodeme of Leishmania major. Trans R Soc Trop Med Hyg (1985) 0.83
Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp Parasitol (1997) 0.82
Evaluation of T cell responses in healing and nonhealing leishmaniasis reveals differences in T helper cell polarization ex vivo and in vitro. Parasite Immunol (2009) 0.81
Identification of highly specific and cross-reactive antigens of Leishmania species by antibodies from Leishmania (Leishmania) chagasi naturally infected dogs. Zoonoses Public Health (2008) 0.80
Cloning and expression analysis of two novel paraflagellar rod domain genes found in Trypanosoma cruzi. Parasitol Res (2005) 0.78
Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev Latinoam Microbiol (2006) 0.77
Vaccination of BALB/c mice with Leishmania donovani derived lipophosphoglycan does not conver cross-protection to L. major infections. East Afr Med J (2003) 0.75
Experimental visceral leishmaniasis in high and low antibody-producer mice (selection IV-A). Rev Soc Bras Med Trop (1999) 0.75
A novel class of Helitron-related transposable elements in maize contain portions of multiple pseudogenes. Plant Mol Biol (2005) 1.73
Single-chain fragment variable antibody piezoimmunosensors. Anal Chem (2005) 1.29
Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur J Immunol (2010) 1.11
Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect (2003) 0.97
Two novel arginine/serine (SR) proteins in maize are differentially spliced and utilize non-canonical splice sites. Biochim Biophys Acta (2005) 0.87
Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: results of a large cross-sectional study. Trans R Soc Trop Med Hyg (2012) 0.86
What determines the success or failure of intracellular cutaneous parasites? Lessons learned from leishmaniasis. Med Microbiol Immunol (2009) 0.85
Cloning and expression analysis of two novel paraflagellar rod domain genes found in Trypanosoma cruzi. Parasitol Res (2005) 0.78
Phenolic Metabolites of Dalea ornata Affect Both Survival and Motility of the Human Pathogenic Hookworm Ancylostoma ceylanicum. J Nat Prod (2016) 0.75
Using a system-on-a-chip implantable device to filter circulating infected cells in blood or lymph. IEEE Trans Nanobioscience (2003) 0.75
Modeling HIV-1 dynamics and the effects of decreasing activated infected T-cell count by filtration. Conf Proc IEEE Eng Med Biol Soc (2004) 0.75
Electroporation-induced cell lysis in SWLA-2 hybridomas. Conf Proc IEEE Eng Med Biol Soc (2006) 0.75
Impaired T-cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome. Exp Dermatol (2015) 0.75